Open Access Open Access  Restricted Access Subscription Access
breast cancer drugs

Current advances in drug delivery systems for treatment of Triple negative breast cancer (TNBC)

Pooja Mittal, Sujata Singh, Archana Singh, Indrakant Kumar Singh


Triple negative breast cancer is known to be the most malignant and aggressive form of breast cancer accompanied with poor prognosis in patients. It is characterized by the absence of expression of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2, making the TNBC cells unresponsive to hormonal therapy. Owing to its molecular heterogeneity and complexity, there are no currently available targeted treatments for TNBC. With only cytotoxic chemotherapy drugs as an established treatment option for TNBC, tumor-targeted delivery of drugs becomes an important parameter to prevent or attenuate chemotherapy-associated side effects and toxicity in TNBC patients. Thus efficient and tumor-targeting drug delivery systems are critically needed for effective treatment of TNBC. This concise review summarizes the most recent findings in the field of cancer-related drug delivery systems, focusing on the treatment of triple negative breast cancer and highlights the future directions and research perspectives in this area.


Triple negative breast cancer; Drug delivery; Liposome; Nanoparticles; Hydrogels; Aptamer; Nanomedicine;

Full Text:


ISSN 2347–9825

Authors/visitors are advised to use Firefox browser for better experience of journal site.

Open Access: Researcher from developing/low economy countries can access the jorunal contents through WHO-HINARI .